Systemic therapy de-escalation in early TNBC marks a shift in oncologic management, emphasizing the reduction of treatment intensity without compromising therapeutic efficacy. While the KEYNOTE-522 ...
Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback